Studies of IGF-I and Klotho Protein in Relation to Anabolic-Androgenic Steroid and Growth Hormone Administrations

Mikael Lehtihet¹, Christina Stephanou², Annica Börjesson², Hasanuzzaman Bhuiyan³, Anton Pohanka²,³ and Lena Ekström²∗

¹ Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ² Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, ³ Doping Control Laboratory, Department of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Sweden

It has been suggested to longitudinally monitor Insulin-like growth factor I (IGF-I) as a biomarker for the detection of recombinant growth hormone (GH). Subsequently, it is of interest to understand any confounders of endogenous IGF-I. Herein we have studied if serum IGF-I concentration is affected by the intake of anabolic androgenic steroids (AAS) and the potential connection between IGF-I and klotho protein. Moreover, the usefulness of klotho as a biomarker for recombinant GH intake was assessed in healthy male volunteers. An ongoing administration of AAS did not affect the levels of IGF-I. Klotho protein was ∼30% higher in men with an ongoing AAS use compared to those with previous (>2 months ago) AAS use, and the serum klotho protein correlated negatively with luteinizing hormone (LH) ($r_s = -0.38, p = 0.04$) and follicle stimulating hormone (FSH) ($r_s = -0.35, p = 0.05$) levels. Serum IGF-I and klotho concentrations showed no correlation in the AAS using population but showed a strong negative correlation in healthy volunteers ($r_s = -0.86, p = 0.006$). The intake of recombinant GH did not affect the serum concentrations of the klotho levels. In conclusion, IGF-I was not affected by supra-physiological AAS doses in men. Interestingly, an association between AAS intake and serum klotho was seen. The usefulness of klotho as an androgen biomarker warrants further studies, whereas klotho can be discarded as a promising biomarker for GH doping.

Keywords: doping, anti-doping, IGF-I, klotho, anabolic androgenic steroid, growth hormone

INTRODUCTION

Anabolic-androgenic steroids (AAS) are used among athletes and in society for their muscle building and performance-enhancing effects (Bhasin et al., 1996). In addition to AAS, recreational and elite athletes may co-use recombinant growth hormone (rGH) and insulin-like growth factor I (IGF-I) for the lipolytic and muscle-enhancing effects noted after GH substitution therapy (Chikani and Ho, 2014). To detect rGH doping, the GH2000 score, including serum IGF-I and procollagen type III N-terminal peptide (P-III-NP) biomarkers, is used in World Anti-Doping Agency (WADA) accredited labs. This population-based score can detect high doses of rGH (Guha et al., 2014), whereas detection of lower doses delivers poor results (Lehtihet et al., 2019).
Lately, it has been discussed that IGF-I could be longitudinally monitored, with or without P-III-NP, in an endocrine passport module to increase the true positive rate (Lehtihet et al., 2019; Marchand et al., 2019). Subsequently, it is of interest to understand how the administration of different drugs, including other doping substances, such as AAS, influences the production of IGF-I. In fact, previous studies on exogenous androgen's effect on IGF-I production in healthy individuals are scarce, but indicate that testosterone administration may lead to an increase in IGF-I serum levels (Hobbs et al., 1993; Veldhuis et al., 2005). However, to our knowledge, IGF-I has not been investigated in relation to the supra-physiological doses often used among athletes engaged in, e.g., bodybuilding.

Klotho protein has been proposed as a clinical biomarker for GH/IGF status, i.e., in the diagnosis and treatment of acromegaly (Sze et al., 2012; Neidert et al., 2013). It is believed that klotho inhibits insulin and IGF-I pathways (Shahmoon et al., 2014), but the correlation between serum klotho and IGF-I in humans has been inconclusive. These differences may be due to the different populations studied (age, disease status) and the kit used for the IGF-I and klotho analyses (Heijboer et al., 2013; Bidlingmaier et al., 2014). Exogenous recGH therapy has been shown to induce klotho concentrations in some healthy subjects (Adema et al., 2018), indicating that klotho protein could act as a putative marker for GH doping. Moreover, a relationship between klotho and androgens has been suggested as klotho gene promoter includes an androgen receptor element (ARE) and testosterone upregulates the messenger RNA (mRNA) and protein klotho expression in kidney cell lines (Hsu et al., 2014).

But to our knowledge, the association of supra-physiological doses of androgens and serum klotho has never been studied.

Here we have studied IGF-I and serum klotho protein in relation to AAS administration in men self-reporting an ongoing or previous AAS use. Moreover, to investigate if serum klotho levels can function as a longitudinal biomarker for GH doping, the klotho protein was studied in relation to GH administration.

MATERIALS AND METHODS

Study Populations

Two cohorts were included in this study: cohort 1 included healthy volunteers administered with recGH and cohort 2 included self-reporting AAS users.

The study population of cohort 1 has been described earlier and included nine healthy male volunteers aged 32–45 years (Lehtihet et al., 2019). The participants were administered with Somatropin (Genotropin®, Pfizer Innovations AB, Strangnas, Sweden) daily for 2 weeks (1 or 4 IU/day) with the primary endpoint to study biomarkers of GH doping. This dose regimen mimics doses reported among AAS users (cohort 2) (Borjesson et al., 2020) and athletes (Marchand et al., 2017). The exclusion criteria for participating in the study included cardiovascular diseases, diabetes, hormonal treatment, being under the influence of abused substances (AAS, opioids, cannabis, cocaine, and amphetamine), malignancy within the last 5 years, or being a member of a sports federation. Three blood samples were collected daily for 3 days prior to recGH administration, and two samples were collected during the treatment period: after 7 and 13 days, respectively. Post-samples were taken 1.5, 3, 24, and 48 h after the last injection. All samples were collected in the morning (7.30–10.30). The study was approved by the Ethics Review Board in Stockholm and written informed consent was obtained from all participants before inclusion in the studies.

Cohort 2 consisted of 30 male individuals self-reporting an AAS use within the last year, aged between 20 and 63 years old. They were recruited from our Anti-Doping Hot-Line via the snowball sampling approach and the population has been described elsewhere (Borjesson et al., 2020). Participation was commenced after oral and written informed consent and the study was approved by the Ethics Review Board in Stockholm. At inclusion, blood and urine samples were taken, and the weight in kilograms and height in meters were measured to calculate the body mass index (BMI) (kg/m²). The participants sat down for 10 min prior to blood sampling, and blood samples were collected from an antecubital vein in serum tubes. Serum was obtained within 4 h by spinning the serum tubes for 10 min at 2,000 g and immediately frozen at −80°C. Testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were measured as described and reported previously. The participants were grouped into current AAS users (<2 months) and former AAS users (last AAS intake 2-12 months ago).

Serum Analyses IGF-I

The IGF-I for the GH administration study was analyzed in our previous report (Lehtihet et al., 2019) and IGF-I analyses of the subjects self-reporting AAS use were quantified with the same WADA accredited method. Briefly, serum IGF-I was measured by a commercially available sandwich-type immunoassay, the Immunotech A15729 IGF-I IRMA (Immunootech SAS, Marseille, France). Six calibrators with different concentrations were used to plot a standard curve. Quality control (QC) samples, QC low and QC high, were used to check the performance of the analysis. Human serum obtained from Sigma Aldrich, ref: H4522, was used as QC low, which gives IGF-I concentration <200 ng/ml, and QC high was prepared by spiking the same serum with recombinant human IGF-I obtained from Invitrogen, ref: PHG0071, which gives concentration >500 ng/ml. A sample volume of 50 µl was applied to the antibody-coated tubes. After the incubation, radioactivity was counted for 5 min with a gamma counter 1282 Compugamma (LKB Wallac). The data were analyzed with spline function curve fitting to determine the concentration of IGF-1 in the samples. To take the age into account, the age-corrected formula calculated from the regression of IGF-1 values of healthy adult subjects determined in Hilding et al. (1999) was applied.

Serum Analyses Klotho

The commercial Human KL(Klotho) ELISA Kit (Catalog Number EKH4368) (Nordic Biosite AB, Täby, Sweden) based on sandwich enzyme-linked immune-sorbent assay technology was used for klotho quantification. To pre-coated anti- klotho
antibody wells, standards (7.8–500 pg/ml) and samples of interest were added followed by a biotin-conjugated anti-klotho antibody as detection antibodies. Horseradish peroxidase (HRP)-Streptavidin was added, and unbound conjugates were washed away with wash buffer. Tetramethylbenzidine (TMB) substrates were used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding an acidic stop solution. The O.D. absorbance was read at 450 nm in a microplate reader (SpectraMax® Plus 384 Microplate Reader, Molecular Devices, LLC, San Jose, CA, USA) and the concentration of klotho was calculated from the standard curve (best-fit-purpose) and multiplied by the dilution factor using the SoftMax Pro Software v1.01. (Molecular Devices, LLC, San Jose, CA, USA). All samples were analyzed in duplicates. The kit has been validated regarding recovery (97–102%) and precision (intra-assay CV < 8%, inter-assay CV < 10%) by the manufacturer (Nordic Biosite, Täby, Sweden). The serum volume used in the ELISA reaction was recommended by the kit provider to be empirically tested. Different serum volumes of 1, 10, 50, and 100 ul were tested from two subjects. For the serum results, 75 ul (1:1.33 dilution) was chosen for the serum analyses as this shows linearity and is within the range of the standard curve. For two participants, one with ongoing AAS use and one with previous AAS use, the klotho levels were far above the standard curve and therefore not included in data analyses. Occasional samples from one of the participants in the GH administration study were outside the standard curve and hence this subject was excluded.

Data Analyses

The statistical analyses were performed using GraphPrism Software version 8 (San Diego, CA, USA). IGF-I and klotho were normally distributed (Shapiro-Wilk test), and the student t-test test was used for comparison between ongoing and previous AAS users, whereas the gonadotropins showed non-normal distribution and the Mann-Whitney U-test was applied. For the correlation analyses, Spearman rank-order correlation or Pearson’s correlation analyses were done depending on the distribution. The coefficient of variation (CV%) was calculated by dividing the SD by the mean value to show intra-individual stability.

Differences were considered significant at $p \leq 0.05$ (2-sided test).

RESULTS

AAS Administration and IGF-I

There was no difference in age and BMI between the ongoing and former AAS users, whereas LH and FSH were significantly lower in those with ongoing AAS use (Table 1).

The IGF-I concentrations (range 55–360 ng/mL) were negatively correlated with age ($r = -0.54$, $p = 0.0006$). Therefore, the age-corrected IGFS values were also applied when comparing IGF-I levels between the groups. There were no significant differences in neither IGF-I and IGFS between AAS users and former AAS users (Table 1). IGF-I and IGFS did not correlate with circulatory levels of the gonadotropins (data not shown).

An ongoing use (i.e., within the last two months) of potential interacting substances, such as insulin ($n = 1$), and GH/IGF-I ($n = 1$), displayed IGF-I values of 160 and 279 ng/ml and IGFS values of −0.30 and −0.59, respectively.

AAS Administration and Klotho

A significant correlation between serum klotho levels and age was noticed, increasing klotho concentrations with age, $r = 0.45$, $p = 0.01$. Figure 1.

Klotho serum levels in relation to the time of last AAS intake revealed significantly higher klotho levels in current AAS users compared to those who reported AAS intake longer than 2 months ago, $p = 0.04$, Table 1.

Negative correlations between FSH and LH with klotho serum levels were observed $r_s = -0.353$, $p = 0.05$ and $r_s = -0.38$, $p = 0.04$.

GH Administration Study

Klotho protein was quantified in serum from eight volunteers from our previous study. Serum samples include samples obtained before recGH administration ($n = 3$ subject) during the treatment period (day 7 and 13) and post GH treatment (+1.5, 3, and 24 h). There were no differences in serum klotho

| TABLE 1 | General characteristics, and hormone values in men with an ongoing AAS (<2 months) and previous AAS (2–12 months). |
| --- | --- | --- |
| Current AAS users ($n = 17$) | Previous AAS users ($n = 14$) | $P$-value |
| Age | 31.5 | 33.5 | ns |
| BMI | 27.3 ± 2.7 | 29.4 ± 3.6 | ns |
| LH (IU/LH) | 0.10 ± 1.8 | 5.3 ± 2.6 | $p < 0.0001$ |
| FSH (IU/L) | 0.14 ± 1.5 | 3.2 ± 3.0 | $p < 0.0001$ |
| IGF-I (pg/mL) | 201 ± 84.1 | 157 ± 41.7 | ns |
| IGFS | −0.41 ± 1.5 | −1.0 ± 0.9 | ns |
| Klotho (pg/mL) | 68.4 ± 20.8 | 49.3 ± 51.5 | $p = 0.04$ |

Values presented as median ±SD. For comparison between groups, Whitney U-test or student T-test were applied depending on the distribution.

BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; IGF-I, insulin growth factor 1.
levels between the different time points investigated ($p = 0.33$, Friedman test), Figure 2. The intra-individual variations of the baseline values were lower (range 4.4–26.5% CV) than the inter-individual variation (range 38–59% CV). The klotho levels showed a strong negative correlation to IGF-I concentration before GH administration ($r = -0.86$, $p = 0.006$), Figure 3A. Also, after GH administration, a similar correlation remained ($r = -0.86$, $p = 0.006$), Figure 3B.
FIGURE 3 | Correlation between IGF-I and klotho in eight healthy volunteers (A) mean of three baseline values (B) mean of four samples taken during (day 7 and 13) and after (+3 and 24 h) recombinant growth hormone (recGH) administration.
DISCUSSION

This is the first study assessing IGF-I and klotho levels in AAS users. It was shown that the intake of supra-physiological doses of AAS was not associated with circulatory IGF-I levels i.e., there was no difference in IGF-I levels between those with current and former AAS use. Previous studies indicate that androgens increase IGF-I secretion via GH (Bondanelli et al., 2003) and it is possible that AAS-induced hypogonadism abrogates GH responsiveness of androgens. This is in line with clinical studies in men with hypogonadism where co-administration with GH was needed to obtain an increase in IGF-I after testosterone administration (Gibney et al., 2005).

We did not see any elevated klotho levels in the AAS user with ongoing use of recGH, and to further strengthen the finding that serum klotho is not affected by GH administration, klotho was analyzed in healthy male volunteers that were administered with recGH for 2 weeks. The intra-subject variation in klotho levels was small (4–26 CV%) and the individual values were not perturbed by recGH administration. The result is in line with Adema et al. who did not observe any significant effects on serum klotho on a group level when a similar recGH dose was administered, even if klotho elevation was noted in a few subjects (Adema et al., 2018). So, it is likely that klotho protein cannot function as a valuable biomarker for doping with recGH. Notably, low levels of klotho may also be detected in urine, particularly in patients with GH excess (Schmid et al., 2013) and it is possible that a different response to recGH would have been observed in urine.

A novel finding was that the ongoing use of AAS was associated with higher serum klotho concentrations. Also, the AAS-induced hypogonadism as reflected by LH and FSH repression correlated to klotho levels. Supra-physiological doses of androgens are known to suppress gonadotropins with fast response (Jarow and Lipschultz, 1990). The degree of suppression and the ability to recover after an AAS cycle depends on the duration of AAS use and the cumulative dose (Tan and Scally, 2009) with most being normalized within 6 months, even though in some cases, it may take up to 1 year as seen in our participants (Borjesson et al., 2020) and elsewhere (Sader et al., 2001). It is possible that as AAS activates the ARE and influences the expression of the klotho gene resulting in elevated protein levels as has been seen in mice (Hsu et al., 2014). Two AREs have been identified in silico in the human klotho promoter region (Hsu et al., 2014) which may explain the higher klotho protein levels in the granulosa cells from women with Polycystic ovary syndrome (PCOS) and hyperandrogenism compared to controls (Mao et al., 2018). Furthermore, a correlation between circulatory T and DHEA and klotho levels in healthy sedentary middle-aged adults has been observed (Dote-Montero et al., 2019). The connection between klotho and androgens in humans warrants further studies.

We noted a strong negative correlation between klotho and IGF-I in the healthy volunteers, whereas in the self-reporting AAS subjects, correlations between klotho and IGF-I/IGFSD could not be discerned. A negative association between klotho and IGF-I is in agreement with the hypotheses that klotho exerts inhibitory effects on the IGF-I pathway as seen in several animal studies (Abramovitz et al., 2011; Shahmoon et al., 2014). A negative association between IGF-I and klotho has been found directly after exercise in healthy subjects (Saghiv et al., 2017). However, in adults with acromegaly positive correlations between IGF-I and klotho have been reported (Sze et al., 2012). Several hypotheses have been proposed for the connection between klotho and the GH/IGF-I pathway, extensively reviewed by Rubinek and Modan-Moses (2016).

The IGF-I and IGFSD values in the AAS users showed large inter-individual variations but were within ranges previously reported in Swedish healthy men (Unden et al., 2002). It is well-known that IGF-I decreases with age and a negative correlation between age and IGF-I were seen among the AAS users. The opposite age pattern was found for klotho, i.e., a strong positive correlation between age and serum klotho concentrations in the AAS users. This is contrary to previous findings where serum klotho levels significantly decreased with age (Koyama et al., 2015). The discrepancy might be that our participants are younger and most of them do not suffer age-associated diseases.

In previous studies it has been observed that athletes display higher IGF-I concentrations than sedentary controls, being highest in athletes engaged in power sports (Eklund et al., 2021). But herein, no differences in IGF-I levels between healthy volunteers and the AAS population were observed. Nor were any differences in serum klotho concentrations between the healthy volunteers and the AAS users noted, but regrettably, both cohorts exhibit lower klotho concentrations that are seen in other studies, including healthy subjects (Dote-Montero et al., 2019). The reason for this may be that the samples have been stored (~80°C) for 3 years and the klotho protein has partly been degraded. However, during method testing, we also included freshly prepared control serum that did show klotho levels in the same range. It is possible that the kit used herein exerts lower sensitivity for klotho than the kits used in other studies, as has been discussed previously (Heijboer et al., 2013). It is possible that only the alternative spliced secreted klotho presents in the circulation (and not the membrane-bound form that has been shedded into the circulation) is detected herein.

There are some limitations with our study that needs to be addressed. Firstly, we only included men in our study populations, and it is possible that gender differences in IGF-I and Klotho response to AAS and GH administration exist. Moreover, regarding the AAS self-reporting population, the timing of the last AAS intake may not be correctly stated. In addition to AAS, several other drugs were used e.g., additional performance-enhancing drugs and drugs taken to eliminate AAS-induced side effects, that might interfere with the results. However, studies of populations self-reporting AAS use is the only way to perform studies of doses often used among bodybuilders, since it is not ethically or medically justified to conduct controlled studies with such doses (60–3,800 mg/week).

Another limitation is that the samples were not taken after overnight fasting but rather at different time points to mimic a doping test situation. IGF-I is known to increase after food intake, particularly proteins. Many of the AAS users eat large amounts of proteins as well as dietary supplements which may be confounder herein.
In conclusion, it has been shown that supra-physiological doses of AAS do not affect circulatory IGF-I concentrations. Instead, the AAS exposure was associated with elevated klotho serum levels and the klotho as a biomarker in relation to androgens deserves further investigation. Klotho levels were not influenced by the administration of recGH and suggested not to be a promising biomarker for GH doping.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Review Board, Stockholm. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

Abramovitz, L., Rubinek, T., Ligumsky, H., Bose, S., Barshack, I., and Avivi, C. (2011). KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in cancer. Clin. Cancer Res. 17, 4254–4266. doi: 10.1158/1078-0432.CCR-10-2749

Adema, A. Y., Roij de van Zuiddewijn, C. L. M., Hoenderop, J. G., de Borst, M. H., Ter Wee, P. M., Heijboer, A. C., et al. (2018). Influence of exogenous growth hormone administration on circulating concentrations of alpha-klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study. BMC Nephrol. 19:327. doi: 10.1186/s12882-018-1114-z

Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., and Phillips, J. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 335, 1–7. doi: 10.1056/NEJM199607053350101

Bidlingmaier, M., Friedrich, N., Emeny, R. T., Spranger, J., Wolthers, O. D., and Rosswall, J. (2014). Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J. Clin. Endocrinol. Metab. 99, 1712–1721. doi: 10.1210/jc.2013-3059

Bondanelli, M., Ambrosio, M. R., Margutti, A., Franceschetti, P., Zatelli, M. C., and degli Uberti, E. C. (2003). Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone. Neuroendocrinology 78, 380–387. doi: 10.1159/000087130

Borjeson, A., Lehtihet, M., Andersson, A., Dahl, M. L., Vicente, V., and Ericsson, M. (2020). Studies of athlete biological passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents. Drug Test Anal. 12, 514–523. doi: 10.1002/dta.2763

Chikani, V., and Ho, K. K. (2014). Action of GH on skeletal muscle function: molecular and metabolic mechanisms. J. Mol. Endocrinol. 52, R107–R123. doi: 10.1530/JME-13-0208

Dote-Montero, M., Amaro-Gahete, F. J., De-la, O. A., Jurado-Fasoli, L., Gutierrez, A., and Castillo, M. J. (2019). Study of the association of DHEAS, testosterone and cortisol with S-Klotho plasma levels in healthy sedentary middle-aged adults. Exp. Gerontol. 121, 55–61. doi: 10.1016/j.exger.2019.03.010

Eklund, E., Hellberg, A., Berglund, B., Brismar, K., and Hirschberg, A. L. (2021). IGF-I and IGFBP-1 in relation to body composition and physical performance in female olympic athletes. Front. Endocrinol. 12:708421. doi: 10.3389/fendo.2021.708421

Gibney, J., Wolthers, T., Johannsson, G., Umpleby, A. M., and Ho, K. K. (2005). Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am. J. Physiol. Endocrinol. Metab. 289, E266–E271. doi: 10.1152/apendocr.00483.2004

Guha, N., Erotokritou-Mulligan, I., Bartlett, C., Nevitt, S. P., Francis, M., and Bassett, E. E. (2014). Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhGH/IrhIGF binding protein-3 complex. J. Clin. Endocrinol. Metab. 99, 2259–2268. doi: 10.1210/jc.2013-3897

Heijboer, A. C., Blankenstein, M. A., Hoenderop, J., de Borst, M. H., and Vervoort, M. G. (2013). Laboratory aspects of circulating alpha-Klotho. Nephrol. Dial. Transplant. 28, 2283–2287. doi: 10.1093/ndt/gft236

Hilding, A., Hall, K., Villaw-Hellerud, I. L., Safi, M., Melin, A. L., and Thoren, M. (1999). Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19–82 years, in relation to those in healthy subjects. J. Clin. Endocrinol. Metab. 84, 2013–2019. doi: 10.1210/jc.84.6.2013

Hobs, C. J., Plymate, S. R., Rosen, C. J., and Adler, R. A. (1993). Testosterone administration increases insulin-like growth factor-I levels in normal men. J. Clin. Endocrinol. Metab. 77, 776–779. doi: 10.1210/jcem.77.3.7693634

Hsu, S. C., Huang, S. M., Lin, S. H., Ka, S. M., Chen, A., and Shih, M. F. (2014). Testosterone increases renal anti-aging klotho gene expression via the androgen receptor-mediated pathway. Biochem. J. 464, 221–229. doi: 10.1042/BJ20140739

Jarow, J. P., and Lipshultz, L. I. (1990). Anabolic steroid-induced hypogonadotropic hypogonadism. Am. J. Med. Sci. 18, 429–431. doi: 10.1097/00000434-199008004-00017

Koyama, D., Sato, Y., Aizawa, M., Makri, T., Kurosawa, M., Kuro-o, M., et al. (2015). Soluble alphaKlotho as a candidate for the biomarker of aging. Biochem. Biophys. Res. Commun. 467, 1019–1025. doi: 10.1016/j.bbrc.2015.10.018

Lehtihet, M., Bhiuyan, H., Dalby, A., Ericsson, M., and Ekstrom, L. (2019). Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting 2 weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers. Drug Test Anal. 11, 411–421. doi: 10.1002/dta.2506

Mao, Z., Fan, L., Yu, Q., Luo, S., Wu, X., Tang, J., et al. (2018). Abnormality of klotho signaling is involved in polycystic ovary syndrome. Reprod. Sci. 25, 372–383. doi: 10.1177/193371191775129

Marchand, A., Buisson, C., Martin, L., Martin, J. A., Molina, A., and Ressiot, D. (2017). Report on an anti-doping operation in Guadeloupe: high number

AUTHOR CONTRIBUTIONS

LE and ML were involved in the concept/design of the GH administration study. LE, ML, and AB were involved in the concept/design of the AAS study. LE, HB, and CS performed the quantification of IGF-I and klotho. LE, CS, and AP were responsible for the acquisition of data. LE wrote the first manuscript draft. All authors were involved in the critical revision of the article. All authors listed met the conditions required for full authorship. All authors contributed to the article and approved the submitted version.

FUNDING

Grants for performing the rhGH administration study and the collection of samples from AAS users were previously supported by WADA and the Swedish Research Council for Sport Science, respectively, and the analyses herein were supported by the Doping Control Laboratory, Karolinska University Hospital.

March 2022 | Volume 4 | Article 829940
of positive cases and inferences about doping habits. Drug Test Anal. 9, 1733–1761. doi: 10.1002/dta.2185
Marchand, A., Martin, J. A., Collot, D., Hoang, O., Roulland, I., and Semence, F. (2019). Combined administration of microdoses of growth hormone and erythropoietin: effects on performance and evaluation of GH detection capability using anti-doping methods. Drug Test Anal. 11, 1698–1713. doi: 10.1002/dta.2674
Neidert, M. C., Sze, L., Zwimpfer, C., Sarnthein, J., Seifert, B., and Frei, K. (2013). Soluble alpha-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur. J. Endocrinol. 168, 575–583. doi: 10.1530/EJE-12-1045
Rubinek, T., and Modan-Moses, D. (2016). Klotho and the growth hormone/insulin-like growth factor 1 axis: novel insights into complex interactions. Vitam Horm. (2016) 101, 85–118. doi: 10.1016/bs.vh.2016.02.009
Sader, M. A., McCredie, R. J., Griffiths, K. A., Wishart, S. M., Handelmann, D. J., and Celemajer, D. S. (2001). Oestriol improves arterial endothelial function in healthy men receiving testosterone. Clin. Endocrinol. 54, 175–181. doi: 10.1046/j.1365-2265.2001.01176.x
Saghiv, M. S., Sira, D. B., Goldhammer, E., and Sagiv, M. (2017). The effects of aerobic and anaerobic exercises on circulating soluble-Klotho and IGF-I in young and elderly adults and in CAD patients. J. Circ. Biomark 6:1849454417733388. doi: 10.1177/1849454417733388
Schmid, C., Neidert, M. C., Tschopp, O., Sze, L., and Bernays, R. L. (2013). Growth hormone and Klotho. J. Endocrinol. 219, R37–57. doi: 10.1530/JOE-13-0285
Shahmoon, S., Rubinek, H., Wolf, I., Cohen, Z. R., Hadani, M., and Shimon, I. (2014). The aging suppressor klotho: a potential regulator of growth hormone secretion. Am. J. Physiol. Endocrinol. Metab. 307, E326–E334. doi: 10.1152/ajpendo.00909.2014
Sze, L., Bernays, R. L., Zwimpfer, C., Wiesli, P., Brandle, M., and Schmid, C. (2012). Excessively high soluble Klotho in patients with acromegaly. J. Intern. Med. 272, 93–97. doi: 10.1111/j.1365-2796.2012.02542.x
Tan, R. S., and Scally, M. C. (2009). Anabolic steroid-induced hypogonadism–towards a unified hypothesis of anabolic steroid action. Med. Hypotheses 72, 723–728. doi: 10.1016/j.mehy.2008.12.042
Unden, A. L., Elofsson, S., Knox, S., Lewitt, M. S., and Brismar, K. (2002). IGF-I a normal population: relation to psychosocial factors. Clin. Endocrinol. 57, 793–803. doi: 10.1046/j.1365-2265.2002.01671.x
Veldhuis, J. D., Frystyk, J., Iranmanesh, A., and Orskov, H. (2005). Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-1/IGFBP-1 concentrations. J. Clin. Endocrinol. Metab. 90, 2941–2947. doi: 10.1210/jc.2004-1314

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lehtihet, Stephanou, Börjesson, Bhuiyan, Pohanka and Ekström. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.